Published May 1, 2014 - More info
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated in animal models by inducing glucosuria with renal glucose transport inhibitors. Here, we examined whether reduction of plasma glucose with a sodium-glucose cotransporter 2 (SGLT2) inhibitor could improve insulin-mediated tissue glucose disposal in patients with type 2 diabetes. Eighteen diabetic men were randomized to receive either dapagliflozin (
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A. Abdul-Ghani, Ralph A. DeFronzo
Original citation: J Clin Invest. 2014;124(2):509–514. doi:10.1172/JCI70704.
Citation for this corrigendum: J Clin Invest. 2014;124(5):2287. doi:10.1172/JCI76184.
An authorship note and a sentence in the Acknowledgments were inadvertently omitted. The correct sentences are below.
Authorship note: Aurora Merovci and Carolina Solis-Herrera contributed equally to this work.
Acknowledgments: Ralph A. DeFronzo and Devjit Tripathy are supported by the South Texas Veterans Health Care System — Audie Murphy Division.
The authors regret the error.